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Early Tn assays had only moderate sensitivity for cardiomyocyte 
injury. Successive generations of assays have increased sensitivi-
ties progressively to the point where a number of assays now 
comply with the recommendation of the Joint ESC/ACCF/
AHA/WHF panel which redefined myocardial infarction (MI) in 
2000, stating that the co-efficient of variation (imprecision) for 
the measurement of troponin should be ≤10% at or below the 
upper limit of normal, which is the 99th percentile of a reference 
control group. This is essentially what defines “high-sensitivity” 
(hs) troponin assays. A second criterion for high sensitivity has 
been proposed(3) viz. that levels should be measurable in at 
INTRODUCTION
Troponins I, T and C are structural proteins bound to the thin 
filaments (actin) in striated muscle. A small amount (5 - 8%) of 
troponin (Tn) exists free in the cytosol. In cardiac myocytes, 
cardiac troponins T and I (cTnT and cTnI) are isoforms distinct 
from those in skeletal myocytes, and monoclonal antibody 
techniques enable measurement of serum levels of cTnI and 
cTnT with high specificity and sensitivity for cardiomyocyte 
injury. Consequently, since their introduction in 1999, serum Tn 
levels have assumed a pivotal role in the diagnosis, prognosis 
and strategy selection for acute coronary syndromes (ACS) 
other than ST-elevation myocardial infarction (STEMI).(1,2)
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ABSTRACT                               The increased sensitivity of high sensitivity cardiac troponin assays comes at a cost of decreased 
specificity, and “false positive” diagnosis of acute coronary syndromes has made clinicians wary of their use, fearing 
unnecessary hospitalisations, angiography and revascularisation. The Ethics and Guidelines Standing Committee of 
SA Heart Association convened a meeting of cardiologists, chemical pathologists, emergency medicine specialists 
and industry representatives to discuss the role of high sensitivity troponin (hsTn) testing. An international expert 
provided guidance, and this Consensus Statement is the product of that meeting. It is recommended that hsTn 
assays be widely adopted as the preferred biomarker for diagnosis of myocardial infarction. Pathology laboratories 
will standardise the units of measurement and the reporting of results. Rules for interpretation of results and algo-
rithms for their application are provided. Separate algorithms apply to troponin T and troponin I, and the several 
troponin I assays on the market each have different numerical values. Use of high sensitivity troponin assays will 
result in earlier diagnosis of myocardial infarction, more reliable ruling out of myocardial infarction, and shortening of 
chest pain triage (to 4 hours), compared to former assays.  SAHeart 2012; 9:210-215
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least 50% of subjects below the 99th percentile. However, 
since this parameter is not likely to impact the diagnostic 
accuracy in ACS and would rule out most contemporary TnI 
assays as not high sensitivity, for the purposes of this guideline, 
we define high sensitivity on the basis of the first criterion alone. 
Since 2009 hs troponin measurements have been proven to 
improve the sensitivity for diagnosis of myocardial infarction.(4,5)
Former troponin assays were either “positive” or “negative” for 
cardiomyocyte injury. However, it is now clear almost every-
one has detectable levels of Tn in their circulation, and parti-
cularly so in the presence of cardiovascular disease such as 
heart failure, hypertension, LV hypertrophy, stable coronary 
artery disease, diabetes or renal dysfunction. This increased 
sensitivity with a concomitant loss of specificity has resulted in 
significant numbers of “false positive” tests for ACS, resulting in 
unnecessary hospitalisation, angiography and in some instances 
revascularisation, thus culminating in unwarranted inconven-
ience and risk to patients as well as the misuse of resources.
The lower specificity of hsTn has made clinicians wary of their 
use, despite increasing evidence supporting their value in diag-
nosis. This situation prompted the SA Heart Association to 
convene a meeting of cardiologists, pathologists, ER physicians 
and industry representatives under the proctorship of an inter-
national expert, Prof H.D. White, to discuss the current status 
of hsTn assays and formulate a statement for guidance on their 
clinical implementation. Apart from the authors, other partici-
pants in this conference were: Prof J.D. Marx, Prof P. Mntla, 
Dr A. Snyders (cardiologists), Dr C. Gous, Dr W. Lubinga 
(emergency medicine specialists), Dr V. Keti, Dr S. Naidu, 
Dr T. Padayachi, Dr J. Tjiattas, Dr P. Tsaagane (chemical patho-
logists), Ms H. de Beer, Ms M. Engelbrecht, (Beckman-Coulter), 
Ms D. Moodley, Dr T. Moodley, Mr S. Roopnarain, Ms G. Caunter 
(Roche), Ms T. Buchmelter, and Mr D. van Graan (Siemens).
The meeting took place at O.R. Tambo International Airport 
on 26 May 2012. What follows is a summary of recommenda-
tions from that meeting.
PRE-ANALYTICAL AND ANALYTICAL ISSUES
There is one hsTnT assay and several hsTnI assays on the 
market. The collection, preservation, storage and transport of 
specimens vary with each assay, which means that the manu-
facturer’s instructions need to be followed. Although serum or 
plasma (preferably heparinised) are appropriate samples, serial 
measurements in a given patient must be done from the same 
sample type to minimise variation. Haemolysed, lipaemic and 
icteric samples may introduce error with some methods and 
should be reported by the laboratory if relevant.
Laboratories currently report hsTn values in a variety of units 
i.e. μg/L or ng/ml e.g. 0.015-0.053, and ng/L or pg/ml e.g. 15-53. 
It has generally been found that the decimal point placement 
causes confusion(6) and it was agreed that, in future, whole 
numbers and specifically ng/L will be used as the unit of meas-
urement by all laboratories. This means that large MI’s will result 
in levels of several thousands. 
The upper limit of normal for hsTn is the 99th percentile of a 
normal reference population. For high sensitivity assays, the co-
efficient of variation (CV) should ideally be less than 10% at or 
below this level, although a CV of 10 - 20% is clinically usable. 
Assays with a CV of >20% should not be used. 
The one hsTnT assay available in South Africa (Roche diag-
nostics) is not harmonised with the TnT assay used previously. 
For values below 100ng/L, the hsTnT value reads 23ng/L higher 
than the former TnT assay, which means that 53ng/L in hsTnT 
is equivalent to the cutoff of 30ng/L used with the former assay. 
The several hsTnI assays on the market are not standardised 
with each other, and there is little prospect of standardisation 
in the foreseeable future. The lowest limit of detection and 
the 99th percentile are also variable and assay-specific. There-
fore it is mandatory that each institution/ laboratory use a 
single TnI assay and familiarise users with its values and ranges. 
Table 1 lists these values for assays that are currently in use in 
South Africa. 
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Falsely high and falsely low test results are rare but possible 
because of heterophile antibodies and human auto-antibodies 
interfering with the assay. 
Results should be reported from the laboratory within 60 
minutes. 
HIGH SENSITIVITY TROPONINS IN ACUTE 
CORONARY SYNDROMES
High sensitivity troponins have a number of significant advan-
tages over the former assays. They allow for earlier identification 
of MI, making former Tn assays, myoglobin and CK-MB redun-
dant. They speed up chest pain triage to 4 hours (vs. 7 hours 
with former assays). They have a superior negative predictive 
value, i.e. are a better “rule-out” test than former assays. They 
are able to predict the risk for subsequent myocardial infarction 
and/or death in a group of patients previously undetected by 
former Tn assays.(7,8)
The improved sensitivity comes at a cost of decreased speci-
ficity. Thus hsTn levels may be mildly raised in a number of 
other clinical settings (Table 2), notably in stable coronary 
artery disease, heart failure, left ventricular hypertrophy, cor 
pulmonale, renal failure and even in the normal general 
population. This lack of specificity can lead to over-diagnosis of 
MI, resulting in unnecessary cardiac consultations, hospitalisa-
tions and inappropriate treatment.
It is recommended that high sensitivity troponins become the 
standard of care for chest pain triage and the diagnosis of car-
diomyocyte injury, replacing forthwith all previously used bio-
markers such as myoglobin, CK-MB, and troponin assays with a 
CV more than 20% at the 99th percentile (which includes 
some point-of-care testing). A method is proposed hereunder 
for the triage of acute chest pain, using hsTn. It must be 
emphasised that careful clinical evaluation particularly of chest 
pain characteristics and a risk assessment e.g. with TIMI or 
GRACE risk scoring, together with accurate ECG interpreta-
tion, are fundamental to the diagnosis of chest pain and that 
hsTn levels must not be seen in isolation. 
*Information from manufacturers
TABLE 1: List of contemporary sensitive troponin assays available 
in South Africa, with the values relevant to the algorithm in 
Figure 1 (ng/L). 
Assay  99th percentile WHO
  (upper limit MI
  of normal) rule-in*
Roche hsTnT  TnT 14 100
Abbott ARCHITECT     TnI 28 300
Beckman AccuTnI       TnI 40 500
Siemens Centaur Ultra    TnI 40 600
Siemens Dimension RxL  TnI 70 600
Siemens Stratus CS      TnI 70 600
TABLE 2: Causes of cardiac troponin elevation (other than acute 
coronary syndromes).
Acute 
Ischaemic mechanism
Acute heart failure
Pulmonary embolism
Tachy-arrhythmias
Brady-arrhythmias
Accelerated hypertension
Hypotension / shock
Sepsis
ARDS
Aortic dissection
Carbon monoxide poisoning
Chronic 
Stable atherosclerotic coronary 
artery disease
Other coronary disease e.g. SLE, 
scleroderma, Kawasaki’s disease, 
transplant vasculopathy
Atrial fi brillation
Chronic heart failure
Chronic renal failure
Hypertension/ LV hypertrophy
Pulmonary arterial hypertension
Aortic valve disease
Hypertrophic cardiomyopathy      
Infi ltration: amyloidosis, 
haemochromatosis, sarcoidosis
Peri-partum cardiomyopathy
Hypothyroidism
Diabetes
Acute 
Other mechanisms
Cardiac contusion
Procedural trauma: 
Cardiac surgery
Uncomplicated PCI
ASD closure
Endomyocardial biopsy
Pacing
ICD shocks
RF/cryo ablation
External cardiac massage
External cardioversion / 
defi brillation
Myo-pericarditis
Endocarditis
Stroke
Tako-tsubo cardiomyopathy
Rhabdomyolysis
COPD exacerbation
Acute renal failure
Burns >30%
Snake venoms
Chemotherapy: Adriamycin, 
5-fl uoro-uracil, herceptin
Sympathomimetic drugs
Strenuous exertion
After non-cardiac surgery
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The consensus of the meeting was that:
 ■ The diagnosis of ST-elevation myocardial infarction is made 
by typical ECG findings in patients with a suggestive clinical 
presentation, and not by elevation of troponins (or any 
other cardiac biomarker). Treatment must be initiated 
immediately and not delayed until assays are completed. 
 ■ Although in unstable angina hsTn remains normal, admission 
for further management may be warranted nevertheless.
 ■ The use of hsTn abolishes the need for other biomarkers, 
specifically myoglobin and CK-MB.(9)
 ■ An initial normal hsTn level in a patient with a reliable 
history of chest pain onset more than 6 hours prior to 
sampling, rules out MI.
 ■ A hsTn value above the WHO cut-off value (Table 1) rules 
in MI. 
 ■ Serial samples demonstrating rising or falling levels of hsTn 
differentiate acute from chronic cardiomyocyte necrosis. 
 ■ The timing of the 2nd of serial samples should be no sooner 
than 3 hours after the first.
 ■ The percentage change (rise or fall) in hsTn levels in 2 
samples 3 hours apart, is used to establish a diagnosis of MI 
when the Tn level is below the WHO cut-off. For TnI a 
50% change in an initial value is diagnostic of MI. In the case 
of TnT, a 50% change in an initial value of <53, or a 20% 
change in an initial value between 53-100ng/L, is diagnostic 
of MI.
 ■ The algorithms in Figure 1 embody the above principles. 
These algorithms are TnT or TnI specific, and in the case of 
TnI, appropriate numerical values need to be inserted from 
Table I, because of lack of standardisation of the assays.(3)
 ■ The definition of MI according to hsTn may in the future 
have to take into account biological variations, viz. age, 
gender, race, active vs sedentary lifestyle and body mass(10) 
but, for the present, the same values apply to all comers.
 ■ The biomarker of choice for the diagnosis of MI associated 
with percutaneous coronary interventions remains contro-
versial.(11) This is firstly because uncomplicated successful 
interventions are often followed by a small Tn rise, and 
secondly because Tn kinetics (ie an abrupt rise followed 
by prolonged elevation) make post-procedural levels diffi-
cult to interpret. This has prompted some interventionalists 
to regress to the use of CK-MB, which results in significant 
underestimation of peri-procedural cardiomyocyte necrosis. 
Aspects of hsTn use in MI diagnosis which require 
clarifi cation through further research include:
 ■ Whether a single undetectable level of hsTn at the time of 
presentation, even earlier than 6 hours from pain onset, 
rules out MI, as has been suggested in one study.(12)
 ■ Whether the time between successive samples can be ab-
breviated to 2 hours, as has been proposed in 3 studies.(9,13,14) 
 ■ Whether changes in absolute values are more reliable than 
relative (%) changes, as one study reported.(15)
 ■ Whether specific treatments or treatment strategies in the 
newly identified group of ACS patients positive for hsTn 
who would have tested “negative” with the former assays, 
are valuable. Preliminary evidence is that this is indeed so.(16)
HIGH SENSITIVITY CARDIAC TROPONINS IN 
CHRONIC SETTINGS
In the general population (Dallas Heart Study), hsTnT was 
detectable in 25% of subjects, compared to conventional Tn 
assays where it was 0.7%.(10) In another study it was detectable 
in 80.9%.(17) 
In patients with stable coronary artery disease in the PEACE 
trial, hsTnT was detectable in 97.7% of subjects, and elevated 
(>13ng/L) in 11.1% of subjects.(18)
In chronic heart failure (in Val-HeFT), hsTnT was detectable in 
92% of subjects (median value 12ng/L) vs 10.4% of subjects 
with a standard TnT assay.(19)
High sensitivity Tn retains prognostic value in all these chronic 
settings, independent of other risk factors. In the general 
population, it predicted all-cause mortality(10) and cardiovascular 
disease risk.(17) In stable coronary artery disease it predicted 
cardiovascular death and heart failure, but not MI.(18) In chronic 
heart failure, it predicted death and hospitalisation for heart 
failure.(19)
The consensus of the meeting was that the use of hsTn for risk 
stratification is not recommended in the general population. 
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<15
<99%
Pain 
>6 hours
Pain 
>6 hours
Pain 
<6 hours
Pain 
<6 hours
Δ<50% Δ<20%Δ>50% Δ>20% Δ = rise or fall
Δ = rise or fall
<53 53-100
99%-WHO MI
>100ng/L
>WHO MI
2nd sample after 3 hours
2nd sample after 3 hours
Discharge
Discharge
Discharge Discharge
Δ<50%
Discharge
Admit
Δ>50%
Admit
Admit Admit
Admit
1st sample TnT
1st sample TnI
Suspected acute coronary syndrome
Suspected acute coronary syndrome
FIGURE 1: Algorithms for interpretation of high-sensitivity cardiac troponin levels in suspected acute coronary syndrome. Note that 
there are different algorithms for TnT and TnI. For TnI, the numerical values indicated in Table I must be inserted.
Notes:
1. Admit = Admit and treat for ACS.
2. Discharge = Discharge – symptomatic treatment / stress test / investigations for other causes of chest pain.
3.  In the TnT algorithm, <53ng/L includes 2 sub-groups: <15 who are “normal”, and 15-52 who are those patients who have abnormal hsTnT but would have tested normal with 
formerly used Tn assays. If the initial value is <15, the second value must exceed 14 for the diagnosis of MI, eg a rise from 8 to 13 is not diagnostic.
4.  On occasions, a 3rd sample at 6 hours may be necessary for clarity of diagnosis. Follow-up measurements after admission for MI may of course be necessary, e.g. for estimation of 
infarct size.  
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There may be some use for establishing prognosis in certain 
patient populations, viz. heart failure, pulmonary embolism and 
renal failure, but it must be emphasised that the primary value 
of this test is for the diagnosis of MI.
CONCLUSION
Dissemination of this consensus statement will include publi-
cation in the SA Heart Journal and the South African Medical 
Journal. It is recommended that pathology laboratories dis-
tribute this statement to their various branches, and the 
Emergency Medicine Society of SA to emergency rooms and 
emergency doctor firms. Furthermore it is recommended that 
pathology laboratories standardise the reporting of high 
sensitivity troponin results, specifically to report values in ng/L, 
and to report percentage change in cases of serial measure-
ment. Clinicians are urged to adopt high sensitivity troponins 
in preference to any other biomarkers for cardiomyocyte 
damage in ACS diagnosis and management. System changes 
are required to make hsTn testing available throughout South 
Africa, in rural as well as urban areas, so as to supplant unsuit-
able point-of-care tests or older assays that may currently be 
in use. The insurance industry should be made aware of 
these recommendations, which will impact on risk and claim 
frequency.
In the future new knowledge is likely to refine this information, 
specifically in regard to absolute vs relative change in hsTn 
levels, and the selection of specific therapies or strategies in 
ACS management according to hsTn levels. An update to this 
guideline will then be necessary. 
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